查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947872

G蛋白偶聯受體（GPCR）市場分析及至2035年預測：按類型、產品類型、服務、技術、應用、最終用戶、功能和設備分類

G-Protein Coupled Receptors (GPCR) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Functionality, Equipment
出版日期: | 出版商: Global Insight Services | 英文 373 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

G蛋白偶聯受體（GPCR）市場預計將從2024年的42億美元成長到2034年的82億美元，複合年成長率約為6.4%。 G蛋白偶聯受體（GPCR）市場涵蓋靶向GPCR藥物的開發和商業化，GPCR在細胞間通訊和訊號傳導中發揮關鍵作用。預計GPCR藥物在心血管疾病、神經系統疾病和代謝性疾病的治療方面具有潛在應用價值，而藥物發現技術的進步和研發投入的增加是推動該市場成長的主要因素。慢性病的增加和個人化醫療方法的進步進一步加速了市場成長，推動了新型療法的開發和對GPCR路徑進行精準標靶化的需求。

由於藥物研發技術和個人化醫療的進步，G蛋白偶聯受體（GPCR）市場正經歷強勁成長。藥物研發領域成長最為迅猛，主要得益於GPCR作為治療標靶在多種疾病治療的應用日益廣泛。在該領域中，生物製藥和小分子藥物尤其引人注目，其中生物製藥憑藉其特異性和高效性佔據主導。診斷應用是成長第二快的領域，這主要得益於對精準醫療和生物標記識別日益成長的需求。在診斷領域，伴隨診斷子領域正因個人化治療通訊協定的需求而蓬勃發展。高通量篩檢和計算建模方面的技術創新能夠高效識別GPCR標靶治療方法，進一步提升了市場潛力。人工智慧和機器學習在GPCR研究中的應用正在最佳化藥物研發流程，預計在不久的將來帶來顯著的進步和盈利的市場機會。

市場區隔
類型 A類、B類、C類、D類、E類
產品 促效劑、拮抗劑、調變器、偏向性配體
服務 篩檢服務、基因分型服務、檢測方法開發、諮詢服務
科技 高通量篩檢、基於細胞的檢測、計算建模
應用領域 藥物研發、腫瘤學、心血管疾病、中樞神經系統疾病、代謝性疾病、呼吸系統疾病
最終用戶 製藥公司、生技公司、學術機構、合約研究組織
功能 訊號傳導、受體脫敏和受體內化
裝置 微孔盤讀數儀、自動化液體處理系統、細胞影像系統

G蛋白偶聯受體（GPCR）市場呈現出多元化的格局，主要企業佔據了相當大的市場佔有率。這主要歸功於其策略性定價和強大的新產品上市管道。該市場的特點是價格競爭激烈，這得益於不斷創新和先進GPCR標靶藥物的推出。這些進步源於對標靶治療和個人化醫療日益成長的需求。北美憑藉在研發方面的大量投入，始終處於領先地位。大型製藥公司透過策略聯盟和併購爭奪市場領導地位，從而塑造了競爭格局。北美和歐洲的法規結構在製定嚴格的市場運營標準方面發揮關鍵作用。這些法規確保了藥物的安全性和有效性，並影響市場動態和成長軌跡。在藥物發現主導的進步和慢性病盛行率快速上升的推動下，GPCR市場蓄勢待發，即將擴張。儘管監管合規和高昂的研發成本等挑戰依然存在，但該市場的創新潛力依然巨大。

主要趨勢和促進因素：

受藥物發現和開發領域重大進展的推動，G蛋白偶聯受體（GPCR）市場正經歷快速成長。關鍵趨勢包括人工智慧（AI）和機器學習的融合，加速了GPCR標靶藥物的設計，並提高了藥物的準確性和療效。先進的成像技術也在推動創新，並促成更具針對性的治療性介入。此外，心血管疾病和癌症等慢性疾病的日益增加也推動了對GPCR標靶治療方法的需求。公共和私人研究經費的增加進一步促進了這一需求，這些經費旨在闡明GPCR的新功能及其在疾病路徑中的作用。個人化醫療的趨勢也是一個關鍵促進因素，因為GPCR為個人化治療方案提供了潛力。此外，人們對未知的GPCR（孤兒GPCR）的興趣日益濃厚，為市場相關人員提供了盈利的機遇，因為這些受體代表著尚未充分開發的領域，並蘊藏著突破性治療方法的潛力。生技公司正在加大研發投入，以充分利用GPCR在治療罕見疾病和複雜疾病方面的巨大潛力。因此，在創新和合作的驅動下，GPCR 市場有望實現強勁擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • A級
    • B級
    • C級
    • D級
    • E級
  • 市場規模及預測：依產品分類
    • 促效劑
    • 反派
    • 數據機
    • 偏向性配體
  • 市場規模及預測：依服務分類
    • 篩檢服務
    • 個人資料服務
    • 檢測方法開發
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 高通量篩檢
    • 基於細胞的檢測
    • 計算建模
  • 市場規模及預測：依應用領域分類
    • 藥物發現
    • 腫瘤學
    • 心血管系統
    • 中樞神經系統
    • 代謝性疾病
    • 呼吸系統
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術機構
    • 合約研究機構
  • 市場規模及預測：依功能分類
    • 訊號傳導
    • 受體脫敏
    • 受體內化
  • 市場規模及預測：依設備分類
    • 微孔盤讀數儀
    • 自動液體處理設備
    • 細胞成像系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Arena Pharmaceuticals
  • Sosei Heptares
  • Morpho Sys
  • Array Bio Pharma
  • Amgen
  • Galapagos NV
  • Axovant Gene Therapies
  • Omeros Corporation
  • Cytokinetics
  • XOMA Corporation
  • Incyte Corporation
  • Ligand Pharmaceuticals
  • Receptos
  • Intercept Pharmaceuticals
  • Neurocrine Biosciences
  • Cerecor
  • Albireo Pharma
  • Karuna Therapeutics
  • Ovid Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS26481

G-Protein Coupled Receptors (GPCR) Market is anticipated to expand from $4.2 billion in 2024 to $8.2 billion by 2034, growing at a CAGR of approximately 6.4%. The G-Protein Coupled Receptors (GPCR) Market encompasses the development and commercialization of drugs targeting GPCRs, pivotal in cellular communication and signal transduction. With applications in treating cardiovascular, neurological, and metabolic disorders, this market is driven by advancements in drug discovery technologies and increasing R&D investments. The surge in chronic diseases and personalized medicine approaches further propels market growth, emphasizing the need for novel therapeutics and precision targeting of GPCR pathways.

The G-Protein Coupled Receptors (GPCR) Market is experiencing robust growth, propelled by advancements in drug discovery and personalized medicine. The drug development segment is the top-performing category, driven by the increasing utilization of GPCRs as therapeutic targets in treating various diseases. Biologics and small molecules within this segment are particularly noteworthy, with biologics leading due to their specificity and efficacy. The second highest performing segment is the diagnostic applications sector, which benefits from the rising demand for precision medicine and biomarker identification. Within diagnostics, the companion diagnostics sub-segment is gaining traction, fueled by the need for tailored treatment protocols. Technological innovations in high-throughput screening and computational modeling are further enhancing the market's potential, enabling more efficient identification of GPCR-targeted therapies. The integration of AI and machine learning in GPCR research is optimizing drug discovery processes, promising significant advancements and lucrative opportunities in the foreseeable future.

Market Segmentation
TypeClass A, Class B, Class C, Class D, Class E
ProductAgonists, Antagonists, Modulators, Biased Ligands
ServicesScreening Services, Profiling Services, Assay Development, Consulting Services
TechnologyHigh Throughput Screening, Cell-Based Assays, Computational Modeling
ApplicationDrug Discovery, Oncology, Cardiovascular, Central Nervous System, Metabolic Disorders, Respiratory
End UserPharmaceutical Companies, Biotechnology Companies, Academic Institutions, Contract Research Organizations
FunctionalitySignal Transduction, Receptor Desensitization, Receptor Internalization
EquipmentMicroplate Readers, Automated Liquid Handlers, Cell Imaging Systems

The G-Protein Coupled Receptors (GPCR) market exhibits a diverse landscape with dominant players holding substantial market share. This is primarily due to strategic pricing strategies and a robust pipeline of new product launches. The market is characterized by competitive pricing, which is influenced by the continuous innovation and introduction of advanced GPCR-targeting drugs. These advancements are driven by increasing demand for targeted therapies and personalized medicine. North America remains at the forefront, propelled by significant investments in research and development. The competitive landscape is shaped by prominent pharmaceutical companies, each vying for leadership through strategic alliances and mergers. Regulatory frameworks in North America and Europe play a pivotal role, setting stringent standards that guide market operations. These regulations ensure safety and efficacy, influencing market dynamics and growth trajectories. The GPCR market is poised for expansion, fueled by advancements in drug discovery technologies and a surge in chronic disease prevalence. Challenges such as regulatory compliance and high development costs persist, yet the market's potential for innovation remains substantial.

Geographical Overview:

The G-Protein Coupled Receptors (GPCR) market is witnessing dynamic growth across various regions, each showcasing unique opportunities. North America leads the charge, propelled by extensive research initiatives and substantial funding from both public and private sectors. The region's robust pharmaceutical industry and focus on innovative drug development further bolster its market leadership. Europe follows closely, driven by strong investments in biomedical research and a well-established healthcare infrastructure. The region's regulatory frameworks and emphasis on personalized medicine enhance its market potential. In the Asia Pacific, the GPCR market is expanding at an impressive rate, supported by increasing healthcare expenditures and burgeoning biopharmaceutical industries. Emerging economies like China and India are pivotal growth pockets, with rising demand for advanced therapeutics. Latin America and the Middle East & Africa are emerging markets with promising prospects. Latin America's growing healthcare sector and increasing R&D activities contribute to its market expansion. Meanwhile, the Middle East & Africa are recognizing the potential of GPCR-targeted therapies in addressing prevalent regional health challenges.

The GPCR market is experiencing nuanced shifts due to global tariffs and geopolitical tensions. In Japan and South Korea, reliance on imported biopharmaceutical inputs subjects them to tariff-induced price volatility, prompting investments in local R&D for GPCR innovations. China, amidst trade tensions, is advancing its self-reliance strategy by enhancing domestic GPCR research capabilities, while Taiwan leverages its robust biotech sector to mitigate geopolitical risks. Globally, the GPCR market is expanding, driven by innovations in drug discovery and personalized medicine. By 2035, the market is poised for substantial growth, contingent on adaptive supply chain strategies and regional collaborations. Middle East conflicts, while primarily affecting energy prices, indirectly influence global supply chains by escalating transportation costs, thereby impacting the cost structure of GPCR-related operations.

Key Trends and Drivers:

The G-Protein Coupled Receptors (GPCR) market is experiencing a surge in growth, propelled by significant advancements in drug discovery and development. A key trend is the integration of artificial intelligence and machine learning to expedite GPCR-targeted drug design, enhancing precision and efficacy. The expanding understanding of GPCR structures through advanced imaging techniques is also driving innovation, allowing for more targeted therapeutic interventions. Moreover, the increasing prevalence of chronic diseases such as cardiovascular disorders and cancer is escalating demand for GPCR-targeted therapies. This is further supported by an uptick in research funding from both public and private sectors, aimed at exploring novel GPCR functions and their roles in disease pathways. The trend towards personalized medicine is another critical driver, as GPCRs offer promising avenues for tailored therapeutic approaches. Additionally, the growing interest in orphan GPCRs presents lucrative opportunities for market players, as these receptors are largely unexplored and hold potential for breakthrough treatments. Biotechnology firms are increasingly investing in GPCR research, seeking to capitalize on the untapped potential of these receptors in treating rare and complex diseases. The GPCR market is thus poised for robust expansion, with innovation and collaboration at the forefront of its evolution.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Class A
    • 4.1.2 Class B
    • 4.1.3 Class C
    • 4.1.4 Class D
    • 4.1.5 Class E
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Agonists
    • 4.2.2 Antagonists
    • 4.2.3 Modulators
    • 4.2.4 Biased Ligands
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Screening Services
    • 4.3.2 Profiling Services
    • 4.3.3 Assay Development
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 High Throughput Screening
    • 4.4.2 Cell-Based Assays
    • 4.4.3 Computational Modeling
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Drug Discovery
    • 4.5.2 Oncology
    • 4.5.3 Cardiovascular
    • 4.5.4 Central Nervous System
    • 4.5.5 Metabolic Disorders
    • 4.5.6 Respiratory
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic Institutions
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Signal Transduction
    • 4.7.2 Receptor Desensitization
    • 4.7.3 Receptor Internalization
  • 4.8 Market Size & Forecast by Equipment (2020-2035)
    • 4.8.1 Microplate Readers
    • 4.8.2 Automated Liquid Handlers
    • 4.8.3 Cell Imaging Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Functionality
      • 5.2.1.8 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Functionality
      • 5.2.2.8 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Functionality
      • 5.2.3.8 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Functionality
      • 5.3.1.8 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Functionality
      • 5.3.2.8 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Functionality
      • 5.3.3.8 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Functionality
      • 5.4.1.8 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Functionality
      • 5.4.2.8 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Functionality
      • 5.4.3.8 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Functionality
      • 5.4.4.8 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Functionality
      • 5.4.5.8 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Functionality
      • 5.4.6.8 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Functionality
      • 5.4.7.8 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Functionality
      • 5.5.1.8 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Functionality
      • 5.5.2.8 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Functionality
      • 5.5.3.8 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Functionality
      • 5.5.4.8 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Functionality
      • 5.5.5.8 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Functionality
      • 5.5.6.8 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Functionality
      • 5.6.1.8 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Functionality
      • 5.6.2.8 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Functionality
      • 5.6.3.8 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Functionality
      • 5.6.4.8 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Functionality
      • 5.6.5.8 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Arena Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sosei Heptares
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Morpho Sys
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Array Bio Pharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Amgen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Galapagos NV
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Axovant Gene Therapies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Omeros Corporation
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Cytokinetics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 XOMA Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Incyte Corporation
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Ligand Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Receptos
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Intercept Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Neurocrine Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Cerecor
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Albireo Pharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Karuna Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Ovid Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us